Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 18/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 0.70 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.67 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.67 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.67 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.67 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.67 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.67 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.67 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397928 | 0.92 | CFTR (0.84) | CFTRMAOBGABRA1GABRB1GABRA5 | |
| SCHEMBL4430677 | 0.89 | CFTR (0.80) | CFTRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL29050150 | 0.89 | CFTR (0.80) | CFTRMAOBGABRA1GABRB1GABRA5 | |
| SCHEMBL398976 | 0.89 | CFTR (0.80) | CFTRMAOBGABRA1GABRB1GABRA5 | |
| SCHEMBL399749 | 0.89 | CFTR (0.80) | CFTRMAOBGABRA1GABRB1GABRA5 | |
| SCHEMBL399686 | 0.89 | CFTR (0.80) | CFTRMAOBGABRA1GABRB1GABRA5 | |
| SCHEMBL30492073 | 0.89 | CFTR (0.80) | CFTRMAOBGABRA1GABRB1GABRA5 | |
| SCHEMBL394208 | 0.89 | CFTR (0.80) | CFTRMAOBGABRA1GABRB1GABRA5 | |
| SCHEMBL395413 | 0.88 | CFTR (0.78) | CFTRMAOBGABRA1GABRB1GABRA5 | |
| SCHEMBL393330 | 0.88 | CFTR (0.78) | CFTRMAOBGABRA1GABRB1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336703-B2 | Process for the synthesis of ivacaftor and related compounds | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2019-07-02 | — | — | US | claimed |
| US-20180127373-A1 | PROCESS FOR THE SYNTHESIS OF IVACAFTOR AND RELATED COMPOUNDS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-05-10 | — | — | US | claimed |
| WO-2016181414-A1 | PROCESS FOR THE SYNTHESIS OF IVACAFTOR AND RELATED COMPOUNDS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-11-17 | — | — | WO | claimed |
| US-20120232059-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-13 | — | — | US | claimed |
| US-20230113225-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230103887-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-11505528-B2 | Inhibitors of microbially induced amyloid | AXIAL THERAPEUTICS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11505528-B2 | Inhibitors of microbially induced amyloid | AXIAL THERAPEUTICS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11414386-B2 | Process for the preparation of ivacaftor and its intermediates | LAURUS LABS LIMITED (IN) | 2022-08-16 | — | — | US | disclosed |
| WO-2022098879-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220133634-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| CN-107501099-B | Modulators of ATP-binding cassette transporters | 沃泰克斯药物股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2007075946-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075946-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1773816-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| WO-2006002421-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103887-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | SNCA, PARK7, PRNP | CFTR 2168/4885MAOB 553/4885GABRA1 1749/4885 |
| US-10336703-B2 | Process for the synthesis of ivacaftor and related compounds | AVPR1A, ACVR1, AVPR2 | CFTR 390/4885MAOB 810/4885GABRA1 485/4885 |
| US-20180127373-A1 | PROCESS FOR THE SYNTHESIS OF IVACAFTOR AND RELATED COMPOUNDS | AVPR1A, ACVR1, AVPR2 | CFTR 390/4885MAOB 810/4885GABRA1 485/4885 |
| US-11505528-B2 | Inhibitors of microbially induced amyloid | SNCA, PARK7, PRNP | CFTR 2168/4885MAOB 553/4885GABRA1 1749/4885 |
| US-20230113225-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | SNCA, PARK7, PRNP | CFTR 2182/4885MAOB 470/4885GABRA1 1748/4885 |
| US-20220133634-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | APC, SNCA, PARK7 | CFTR 760/4885MAOB 852/4885GABRA1 2343/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | CFTR 1/4885MAOB 3796/4885GABRA1 974/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | CFTR 1/4885MAOB 3602/4885GABRA1 689/4885 |
| US-20120232059-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | CFTR 1/4885MAOB 3286/4885GABRA1 865/4885 |
| US-11414386-B2 | Process for the preparation of ivacaftor and its intermediates | ACVR1, SLC10A2, CYP4X1 | CFTR 119/4885MAOB 2636/4885GABRA1 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.